PBYI Q4 2017 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M

Gross Profit

$18M81.0% margin

Operating Income

-$64M-294.4% margin

Net Income

-$64M-296.8% margin

EPS (Diluted)

$-1.71

QoQ Revenue Growth

+255.4%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$86M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$166M

Total Liabilities

$112M

Stockholders' Equity

$53M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$0	—
Gross Profit	$18M	$0	—
Operating Income	-$64M	-$73M	+12.8%
Net Income	-$64M	-$73M	+11.8%